Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:13:40.470Z.
Calculation as of: 2026-10-06T19:13:40.470Z.
Quote observation: 2026-10-06T19:10:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bc1f4c18f19876ab16fbc38bb33c2f59d02ebf5b777874ee4386cd5e587f8fe3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$627.21M
EV/FCF Ratio
14.85x
TTM Avg
38.21x
3Y Avg
38.21x
5Y Avg
21.28x
Market Cap
$600.99M
EV/FCF Ratio
4.95x
TTM Avg
12.45x
3Y Avg
11.11x
5Y Avg
9.59x
Market Cap
$595.13M
EV/FCF Ratio
1065.48x
TTM Avg
684.49x
3Y Avg
684.49x
5Y Avg
386.65x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $621.71M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $622.66M | N/A | 710.97x | 756.83x | 756.83x |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $627.21M | 14.85x | 38.21x | 38.21x | 21.28x |
| Climb Bio, Inc. (CLYM)vs › | $612.71M | N/A | 370.81x | 370.81x | 370.81x |
| Aura Biosciences, Inc. (AURA)vs › | $633.57M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.99M | 4.95x | 12.45x | 11.11x | 9.59x |
| AngioDynamics, Inc. (ANGO)vs › | $595.13M | 1065.48x | 684.49x | 684.49x | 386.65x |
| Prime Medicine, Inc. (PRME)vs › | $654.74M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.84M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $583.30M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
